Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Johnson & Johnson will acquire Momenta Pharmaceuticals, which has been developing nipocalimab (M281) for the treatment of myasthenia gravis (MG). The process, which involves an all-cash deal totaling about ... Read more
Immunovant is preparing to launch a Phase 3 trial of its investigational candidate IMVT-1401 in patients with myasthenia gravis (MG); it may lead to the treatment’s approval for this indication, ... Read more
Defects in mitophagy — the process that degrades defective mitochondria, the cell compartments responsible for producing energy — in certain types of immune cells may cause myasthenia gravis (MG), ... Read more
Rituximab seems to be more effective in newly-diagnosed patients with generalized myasthenia gravis (gMG), compared to people at more advanced stages of the disease, a study has found. Investigators ... Read more
UCB has completed its acquisition of Ra Pharmaceuticals, priced at about $2.3 billion, meaning that zilucoplan — an investigational treatment for myasthenia gravis (MG) — is being added to ... Read more
Ra Pharmaceuticals announced the first patient enrolled in RAISE, the company’s Phase 3 clinical trial assessing the effectiveness of zilucoplan as a therapy for generalized myasthenia gravis (gMG), has ... Read more
Pin It on Pinterest